Enoxaparin
- TRADE NAMES: Clexane (Sanofi-Aventis); Klexane; Lovenox (Sanofi-Aventis)
- INDICATIONS: Prevention of deep vein thrombosis, ischemic complications of unstable angina and non-Q wave myocardial infarction; treatment of acute ST-segment elevation myocardial infarction
- CLASS: Heparin, low molecular weight
- HALF-LIFE: 4.5 hours
ACE inhibitors, Angiotensin II receptor antagonists, Anticoagulants, Aspirin, Butabarbital, Clopidogrel, Danaparoid, Diclofenac, Dipyridamole, Drotrecogin Alfa, Iloprost, Infused nitrates, Ketorolac, NSAIDs, Platelet inhibitors, Rivaroxaban, Salicylates, Sulfinpyrazone
PREGNANCY CATEGORY: B
Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture.
Contra-indicated in patients with active major bleeding; thrombocytopenia with a positive in vitro test for anti-platelet antibody in the presence of enoxaparin; hypersensitivity to heparin or pork products; hypersensitivity to benzyl alcohol (multi-dose formulation only).
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of enoxaparin in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 11/14/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric